155 related articles for article (PubMed ID: 27886643)
1. Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.
Coltelli L; Fontana A; Lucchesi S; Ginocchi L; Bocci G; Filidei M; Scalese M; Arrighi G; Finale C; Marcucci L; Goletti O; Salvadori B; Ferrarini I; Bona E; Falcone A; Allegrini G
Breast; 2017 Feb; 31():186-191. PubMed ID: 27886643
[TBL] [Abstract][Full Text] [Related]
2. Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.
Coltelli L; Finale C; Musettini G; Fontana A; Barletta MT; Lucarini AR; Fabiani I; Scalese M; Bocci G; Masini LC; Soria G; Cupini S; Arrighi G; Barbara C; De Maio E; Salvadori B; Marini A; Pellino A; Stasi I; Emdin M; Giaconi S; Marcucci L; Allegrini G
Clin Exp Med; 2023 Dec; 23(8):5113-5120. PubMed ID: 37634231
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Gil-Gil MJ; Bellet M; Morales S; Ojeda B; Manso L; Mesia C; Garcia-Martínez E; Martinez-Jáñez N; Melé M; Llombart A; Pernas S; Villagrasa P; Blasco C; Baselga J
Breast Cancer Res Treat; 2015 Jun; 151(3):597-606. PubMed ID: 25981896
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
8. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
9. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
10. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C; Fornier M; Sugarman S; Troso-Sandoval T; Lake D; D'Andrea G; Seidman A; Sklarin N; Dickler M; Currie V; Gilewski T; Moynahan ME; Drullinsky P; Robson M; Wasserheit-Leiblich C; Mills N; Steingart R; Panageas K; Norton L; Hudis C
J Clin Oncol; 2008 Mar; 26(8):1216-22. PubMed ID: 18323546
[TBL] [Abstract][Full Text] [Related]
11. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Romond EH; Jeong JH; Rastogi P; Swain SM; Geyer CE; Ewer MS; Rathi V; Fehrenbacher L; Brufsky A; Azar CA; Flynn PJ; Zapas JL; Polikoff J; Gross HM; Biggs DD; Atkins JN; Tan-Chiu E; Zheng P; Yothers G; Mamounas EP; Wolmark N
J Clin Oncol; 2012 Nov; 30(31):3792-9. PubMed ID: 22987084
[TBL] [Abstract][Full Text] [Related]
12. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
[TBL] [Abstract][Full Text] [Related]
13. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Morris PG; Iyengar NM; Patil S; Chen C; Abbruzzi A; Lehman R; Steingart R; Oeffinger KC; Lin N; Moy B; Come SE; Winer EP; Norton L; Hudis CA; Dang CT
Cancer; 2013 Nov; 119(22):3943-51. PubMed ID: 24037735
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients.
Kurtz JE; Rousseau F; Meyer N; Delozier T; Serin D; Nabet M; Djafari L; Dufour P
Oncology; 2007; 73(3-4):210-4. PubMed ID: 18424884
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
16. A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients.
Wildiers H; Jurcut R; Ganame J; Herbots L; Neven P; De Backer J; Denys H; Cocquyt V; Rademakers F; Voigt JU; Paridaens R
Crit Rev Oncol Hematol; 2008 Aug; 67(2):133-8. PubMed ID: 18308582
[TBL] [Abstract][Full Text] [Related]
17. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
18. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
McArthur HL; Rugo H; Nulsen B; Hawks L; Grothusen J; Melisko M; Moasser M; Paulson M; Traina T; Patil S; Zhou Q; Steingart R; Dang C; Morrow M; Cordeiro P; Fornier M; Park J; Seidman A; Lake D; Gilewski T; Theodoulou M; Modi S; D'Andrea G; Sklarin N; Robson M; Moynahan ME; Sugarman S; Sealey JE; Laragh JH; Merali C; Norton L; Hudis CA; Dickler MN
Clin Cancer Res; 2011 May; 17(10):3398-407. PubMed ID: 21350003
[TBL] [Abstract][Full Text] [Related]
19. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
Russell SD; Blackwell KL; Lawrence J; Pippen JE; Roe MT; Wood F; Paton V; Holmgren E; Mahaffey KW
J Clin Oncol; 2010 Jul; 28(21):3416-21. PubMed ID: 20530275
[TBL] [Abstract][Full Text] [Related]
20. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
Abu-Khalaf MM; Juneja V; Chung GG; DiGiovanna MP; Sipples R; McGurk M; Zelterman D; Haffty B; Reiss M; Wackers FJ; Lee FA; Burtness BA
Breast Cancer Res Treat; 2007 Sep; 104(3):341-9. PubMed ID: 17051423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
